Showing results (151-160 of 255) with videos related to
Sort By:
Pageof 26
Journal of the National Cancer Institute|December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma ResearchGrzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.British Journal of Haematology|October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601Brian G Till, Hongli Li, Steven H Bernstein, et al.Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2022
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC ConsortiumAngie Mae Rodday, Susan K Parsons, Jenica N Upshaw, et al.Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.Journal of Geriatric Oncology|October 23, 2021
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty toolElizabeth A Brem, Hongli Li, Anne W Beaven, et al.JAMA Cardiology|March 29, 2023
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell LymphomaJenica N Upshaw, Jason Nelson, Angie Mae Rodday, et al.Pageof 26